Assay-Ready Biospecimens for Translational and Clinical Research

Biospecimens are human-derived samples—such as blood, tissue, plasma, or cells—collected for research and therapeutic development purposes. They are critical for translational and clinical research, allowing scientists to study disease mechanisms, identify biomarkers, and develop diagnostics and therapies. At Discovery, we offer assay-ready biospecimens with comprehensive characterization and rapid delivery to support projects across oncology, infectious disease, immunology, and more.

Choosing the right biospecimen depends on your study goals, analyte targets, and downstream applications. Our team can guide you in choosing the optimal sample types and cohorts based on parameters such as disease state, sample format (e.g., FFPE vs. fresh frozen), patient or donor demographics, and biomarker preservation requirements. Connect with a Discovery biospecimen expert to learn more.

Discovery’s disease-specific biospecimen inventory spans a wide range of disease areas, including oncology (e.g., breast, lung, colon cancers), autoimmune conditions, infectious diseases (e.g., COVID-19, HIV, HBV), metabolic disorders, and rare diseases. We offer both diseased and normal control samples from diverse donors.

All biospecimens at Discovery are collected under IRB-approved protocols with informed consent and adherence to HIPAA, GDPR, and applicable regulatory guidelines. Our global network of donor sites enables rapid procurement and standardized processing, including plasma separation, fixation, cryopreservation, and shipment in assay-ready formats.

Yes, Discovery offers both off-the-shelf and prospective biospecimen collection services. We specialize in custom donor recruitment and collection protocols to meet your study’s specific inclusion criteria, timelines, and analytical needs. Contact us to discuss your custom collection needs.

Yes. Discovery has one of the world’s largest inventory of matched biospecimen samples These matched sets come from the same donor, such as FFPE tissue plus plasma, PBMCs, and serum, enabling multi-omics analysis, biomarker discovery, and validation across compartments.

Many of our biospecimens include detailed clinical annotations such as diagnosis, stage, treatment history, demographics, and molecular test results. This enables precision cohort selection and correlation with study outcomes. Additionally, Discovery has 2-year cancer patient follow-up longitudinal data for FFPE tissues, double-spun plasma, and DTCs from nearly 400 patients, detailing treatment regimens, response rates, relapse or recurrence instances, survival outcomes, disease progression, co-morbidities, and additional tests conducted over the 2-year period following sample collection. Connect with a Discovery biospecimen expert to learn more.